{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:story:b4ad0ab7-f9ba-416f-9e1b-104c20743aa3", "type": "composite", "version": "1", "versioncreated": "2026-10-23T13:00:28.658081Z", "firstcreated": "2026-10-23T06:01:43.747458Z", "pubstatus": "usable", "language": "ru", "headline": "Вакцина от меланомы снижает риск рецидива на 42%", "description_text": "Компании Merck и Moderna представили полные результаты третьей фазы испытаний персонализированной мРНК-вакцины интисмеран: у пациентов с меланомой риск рецидива или смерти снизился на 42%.", "associations": {"item-0": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:2c0f7997-a7e2-4678-a6fb-1cdf063b90a1", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-10-23T06:05:19.769469Z", "firstcreated": "2026-10-23T06:01:43.747458Z", "pubstatus": "usable", "urgency": 5, "language": "ru", "headline": "Вакцина от меланомы снижает риск рецидива на 42%", "byline": "Виктор Анисимов", "located": "RU", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Пладром", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Пладром”. Set rel=canonical to https://pladrom.com/nauka/vaktsina-ot-melanomy-snizhaet-risk-retsidiva-na-42/ when publishing on the web.", "description_text": "Компании Merck и Moderna представили полные результаты третьей фазы испытаний персонализированной мРНК-вакцины интисмеран: у пациентов с меланомой риск рецидива или смерти снизился на 42%.", "altids": {"mosaic": "2c0f7997-a7e2-4678-a6fb-1cdf063b90a1", "story": "b4ad0ab7-f9ba-416f-9e1b-104c20743aa3", "slug": "vaktsina-ot-melanomy-snizhaet-risk-retsidiva-na-42"}, "subject": [{"name": "Science", "rel": "direct", "literal": "science", "code": "medtop:13000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/13000000"}], "place": [{"name": "RU", "literal": "ru", "code": "RU", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:d6de731f-353f-4b14-bc78-edc34468c215", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report", "description_text": "Вакцина от меланомы снижает риск рецидива на 42%", "copyrightholder": "static01.nyt.com", "copyrightnotice": "Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report", "usageterms": "Picture belongs to the source publication: address and terms are delivered, the file is not.", "altids": {"wireva": "d6de731f-353f-4b14-bc78-edc34468c215"}, "extra": {"wireva:delivery_mode": "link_only", "wireva:rights": {"licence": "", "licence_url": "", "licence_raw": "RSS source", "licence_verified_at": "2026-10-23T06:05:19.785622Z", "attribution_required": true, "attribution_text": "Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "static01.nyt.com", "source_url": "https://static01.nyt.com/images/2026/08/05/multimedia/22WELL-CANCER-VAX-RESULTS-1/22WELL-CANCER-VAX-RESULTS-1-mediumSquareAt3X.jpg", "source_page_url": "https://static01.nyt.com/images/2026/08/05/multimedia/22WELL-CANCER-VAX-RESULTS-1/22WELL-CANCER-VAX-RESULTS-1-mediumSquareAt3X.jpg", "our_page_url": "https://pladrom.com/nauka/vaktsina-ot-melanomy-snizhaet-risk-retsidiva-na-42/"}, "wireva:role": "lead"}, "renditions": {"source": {"href": "https://static01.nyt.com/images/2026/08/05/multimedia/22WELL-CANCER-VAX-RESULTS-1/22WELL-CANCER-VAX-RESULTS-1-mediumSquareAt3X.jpg", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:b4ad0ab7-f9ba-416f-9e1b-104c20743aa3", "slug": "42-20261023", "status": "updated", "languages": ["en", "ru"], "item_count": 2, "is_breaking": false}, "wireva:rights": {"class": "agency_original", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Пладром", "canonical_required": true, "canonical_url": "https://pladrom.com/nauka/vaktsina-ot-melanomy-snizhaet-risk-retsidiva-na-42/", "linkback_required": true, "licence": "Wireva subscriber licence", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "agency_original_verified", "needs_review": false}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "multi_source", "independent_confirmations": 2, "official_source_used": false, "used_press_release": false, "public_interest": false, "ai_disclosure_required": false, "ai_disclosure_text": "", "independence_check": {"status": "passed", "score": 0.111, "checked_at": "2026-10-23T06:05:19.783092Z"}, "sources": [{"url": "https://www.nytimes.com/2026/10/22/well/cancer-vaccine-melanoma-merck-moderna.html", "title": "mRNA cancer vaccine slashes melanoma death or recurrence risk by 42%", "publisher": "nytimes.com", "type": "rss", "role": "primary", "official": false, "retrieved_at": "2026-10-23T06:05:19.773862Z", "published_at": "2026-10-22T19:51:15Z"}, {"url": "https://www.independent.co.uk/news/world/americas/mrna-cancer-vaccine-moderna-merck-b3071828.html", "title": "", "publisher": "independent.co.uk", "type": "rss", "role": "supporting", "official": false, "retrieved_at": "2026-10-23T06:05:19.771669Z", "published_at": null}, {"url": "https://www.theguardian.com/society/2026/oct/23/mrna-vaccine-melanoma-cancer-breakthrough-australia", "title": "", "publisher": "theguardian.com", "type": "rss", "role": "supporting", "official": false, "retrieved_at": "2026-10-23T06:05:19.774879Z", "published_at": null}]}, "wireva:publication": {"name": "Пладром", "domain": "pladrom.com", "country": "RU", "url": "https://pladrom.com/nauka/vaktsina-ot-melanomy-snizhaet-risk-retsidiva-na-42/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/2c0f7997-a7e2-4678-a6fb-1cdf063b90a1", "html": "https://wireva.mib.news/item/2c0f7997-a7e2-4678-a6fb-1cdf063b90a1/vaktsina-ot-melanomy-snizhaet-risk-retsidiva-na-42/", "story": "https://wireva.mib.news/story/42-20261023/"}, "wireva:metrics": {"word_count": 309, "char_count": 2490, "reading_time_seconds": 178}}}, "item-1": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:94654a24-fc40-40f8-9de9-26f86c45d7cf", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-10-23T13:05:19.265059Z", "firstcreated": "2026-10-23T13:00:28.658081Z", "pubstatus": "usable", "urgency": 5, "language": "en", "headline": "Personalized mRNA Vaccine Cuts Melanoma Recurrence and Death Risk in Phase III Trial", "byline": "Logan Weston", "located": "United States", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Science Official", "usageterms": "Monitoring item. Headline, short extract and the source link may be shown. Do not republish the full text.", "description_text": "A custom-made mRNA vaccine, intismeran, significantly reduces the risk of melanoma recurrence or death within two years, marking the first positive phase III result for an individualized cancer vaccine.", "altids": {"mosaic": "94654a24-fc40-40f8-9de9-26f86c45d7cf", "story": "b4ad0ab7-f9ba-416f-9e1b-104c20743aa3", "slug": "personalized-mrna-vaccine-cuts-melanoma-recurrence-and-death-risk-in-phase-iii-trial"}, "subject": [{"name": "Health", "rel": "direct", "literal": "health", "code": "medtop:07000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/07000000"}], "place": [{"name": "United States", "literal": "us", "code": "US", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "body_text": "A custom-made mRNA vaccine, intismeran, significantly reduces the risk of melanoma recurrence or death within two years, marking the first positive phase III result for an individualized cancer vaccine.", "extra_body_note": "Extract only — see rights.class = link_only.", "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:95e8bff4-411e-416c-b418-73d41c161c91", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer", "description_text": "COVID-19 mRNA Vaccination Around Immunotherapy Start Linked to Modest Early Survival Gains in Cancer Patients", "copyrightholder": "en.wikipedia.org", "copyrightnotice": "COVID-19 vaccine", "usageterms": "File-level licence not yet resolved from Commons; fetch the original for exact terms.", "altids": {"wireva": "95e8bff4-411e-416c-b418-73d41c161c91"}, "extra": {"wireva:delivery_mode": "preview_and_link", "wireva:rights": {"licence": "Wikimedia — licence per file", "licence_url": "https://commons.wikimedia.org/wiki/Commons:Reusing_content_outside_Wikimedia", "licence_raw": "Wikipedia page image", "licence_verified_at": "2026-10-23T13:05:19.308192Z", "attribution_required": true, "attribution_text": "COVID-19 vaccine", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "en.wikipedia.org", "source_url": "https://en.wikipedia.org/wiki/COVID-19_vaccine", "source_page_url": "https://en.wikipedia.org/wiki/COVID-19_vaccine", "our_page_url": "https://scienceofficial.org/medicine/personalized-mrna-vaccine-cuts-melanoma-recurrence-and-death-risk-in-phase-iii-trial/"}, "wireva:role": "lead"}, "renditions": {"preview": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/e661e78a93135d1086a93546b28c92996f4d84e4659ed33744e84b53a6a0d7b8.jpg", "mimetype": "image/jpeg", "width": 1280, "height": 720}, "source": {"href": "https://en.wikipedia.org/wiki/COVID-19_vaccine", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:b4ad0ab7-f9ba-416f-9e1b-104c20743aa3", "slug": "42-20261023", "status": "updated", "languages": ["en", "ru"], "item_count": 2, "is_breaking": false}, "wireva:rights": {"class": "link_only", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Science Official", "canonical_required": true, "canonical_url": "https://scienceofficial.org/medicine/personalized-mrna-vaccine-cuts-melanoma-recurrence-and-death-risk-in-phase-iii-trial/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 280, "decided_by_rule": "derivation_failed", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "multi_source", "independent_confirmations": 3, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.", "independence_check": {"status": "failed", "score": 0.6, "checked_at": "2026-10-23T13:05:19.302282Z"}, "sources": [{"url": "https://www.theguardian.com/society/2026/oct/23/mrna-vaccine-melanoma-cancer-breakthrough-australia", "title": "Moderna mRNA vaccine almost halves the risk of skin cancer returning", "publisher": "theguardian.com", "type": "rss", "role": "primary", "official": false, "retrieved_at": "2026-10-23T13:05:19.282304Z", "published_at": "2026-10-22T23:00:00Z"}, {"url": "https://www.nature.com/articles/d41586-026-03417-0", "title": "", "publisher": "nature.com", "type": "rss", "role": "supporting", "official": false, "retrieved_at": "2026-10-23T13:05:19.270109Z", "published_at": null}, {"url": "https://www.nature.com/articles/s41591-026-04734-7", "title": "", "publisher": "nature.com", "type": "rss", "role": "supporting", "official": false, "retrieved_at": "2026-10-23T13:05:19.272896Z", "published_at": null}, {"url": "https://www.sciencedaily.com/releases/2026/10/261022081309.htm", "title": "", "publisher": "sciencedaily.com", "type": "rss", "role": "supporting", "official": false, "retrieved_at": "2026-10-23T13:05:19.276251Z", "published_at": null}, {"url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02030-1/fulltext?rss=yes", "title": "", "publisher": "thelancet.com", "type": "rss", "role": "supporting", "official": false, "retrieved_at": "2026-10-23T13:05:19.285465Z", "published_at": null}]}, "wireva:publication": {"name": "Science Official", "domain": "scienceofficial.org", "country": "US", "url": "https://scienceofficial.org/medicine/personalized-mrna-vaccine-cuts-melanoma-recurrence-and-death-risk-in-phase-iii-trial/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/94654a24-fc40-40f8-9de9-26f86c45d7cf", "html": "https://wireva.mib.news/item/94654a24-fc40-40f8-9de9-26f86c45d7cf/personalized-mrna-vaccine-cuts-melanoma-recurrence-and-death-risk-in-phase-iii-trial/", "story": "https://wireva.mib.news/story/42-20261023/"}, "wireva:metrics": {"word_count": 481, "char_count": 3249, "reading_time_seconds": 232}}}}, "extra": {"wireva:languages": ["en", "ru"], "wireva:status": "updated", "wireva:item_count": 2}}